January 2025 – First Half
Recent advances in hair loss research, particularly for androgenetic alopecia (AGA) and alopecia areata (AA), have been promising. Platelet-rich plasma (PRP) shows potential in increasing hair density and thickness, especially with microneedling or minoxidil. Sublingual minoxidil effectively increases hair fiber diameter, suggesting reversal of follicle miniaturization. Combining fractional CO2 laser with topical dutasteride yields superior results for male AGA. The BRAVE-AA trials confirm baricitinib’s efficacy in severe AA cases, with additional support for pediatric AA and atopic dermatitis. Tofacitinib shows promise for resistant nail changes in AA, achieving complete regrowth in a pediatric case. Natural treatments like Astragalus sinicus extracts and soybean extract promote hair growth through various pathways. Sulforaphane accelerates dihydrotestosterone degradation, benefiting androgenic alopecia. Vitamin B12 and vitamin D3 are crucial for hair and nerve health, with vitamin D3 deficiency linked to AA. Ultraviolet-induced fluorescence trichoscopy (UVFT) and advanced dermoscopy techniques enhance diagnostic accuracy and treatment monitoring, though full regrowth remains uncertain.
The community intensely debates finasteride and dutasteride, with a 25-year user citing sexual dysfunction and brain fog, while others report positive regrowth with minimal side effects, fueling ongoing safety and efficacy discussions and interest in alternatives like ketoconazole shampoo and microneedling. Concerns about minoxidil’s pet toxicity lead some to oral forms, while PP405’s potential for hair regrowth via stem cell manipulation is met with skepticism, likened to minoxidil. Eirion Therapeutics’ ET-02 shows promise in trials, possibly surpassing minoxidil by activating follicle stem cells. Microneedling’s effectiveness is favored over laser therapy for cost and efficacy, amidst satirical discussions reflecting mixed feelings on current treatments and future breakthroughs.